NCT06069687View on ClinicalTrials.gov

Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Spastic Paraplegia Type 50
Interventions
BIOLOGICAL

MELPIDA

A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER